NeoGenomics (NEO) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook

October 26, 2016 8:42 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

NeoGenomics (NASDAQ: NEO) reported Q3 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $60.8 million versus the consensus estimate of $61 million.

GUIDANCE:

NeoGenomics sees FY2016 EPS of $0.14-$0.16, versus prior guidance of $0.08-$0.13 and the consensus of $0.13. NeoGenomics sees FY2016 revenue of $245-250 million, versus the consensus of $247.0 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance, Hot Guidance

Related Entities

Earnings

Add Your Comment